What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?

Autor:	Aman MG; The Ohio State University. Electronic address: aman.1@osu.edu., Bukstein OG; University of Texas-Houston Medical School., Gadow KD; Stony Brook University., Arnold LE; The Ohio State University., Molina BS; University of Pittsburg School of Medicine., McNamara NK; Case Western Reserve University., Rundberg-Rivera EV; Stony Brook University Medical Center., Li X; The Ohio State University., Kipp H; University of Pittsburg School of Medicine., Schneider J; Stony Brook University Medical Center., Butter EM; Nationwide Children's Hospital of Columbus., Baker J; Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center., Sprafkin J; Stony Brook University., Rice RR Jr; The Ohio State University., Bangalore SS; University of Pittsburg School of Medicine., Farmer CA; The Ohio State University., Austin AB; The Ohio State University., Buchan-Page KA; The Ohio State University., Brown NV; The Ohio State University., Hurt EA; The Ohio State University., Grondhuis SN; The Ohio State University., Findling RL; Johns Hopkins University.
Jazyk:	angličtina
Zdroj:	Journal of the American Academy of Child and Adolescent Psychiatry [J Am Acad Child Adolesc Psychiatry] 2014 Jan; Vol. 53 (1), pp. 47-60.e1. Date of Electronic Publication: 2013 Nov 18.
DOI:	10.1016/j.jaac.2013.09.022
Abstrakt:	Objective: Although combination pharmacotherapy is common in child and adolescent psychiatry, there has been little research evaluating it. The value of adding risperidone to concurrent psychostimulant and parent training (PT) in behavior management for children with severe aggression was tested. Method: One hundred sixty-eight children 6 to 12 years old (mean age 8.89 ± 2.01 years) with severe physical aggression were randomized to a 9-week trial of PT, stimulant (STIM), and placebo (Basic treatment; n = 84) or PT, STIM, and risperidone (Augmented treatment; n = 84). All had diagnoses of attention-deficit/hyperactivity disorder and oppositional-defiant disorder (n = 124) or conduct disorder (n = 44). Children received psychostimulant (usually Osmotic Release Oral System methylphenidate) for 3 weeks, titrated for optimal effect, while parents received PT. If there was room for improvement at the end of week 3, placebo or risperidone was added. Assessments included parent ratings on the Nisonger Child Behavior Rating Form (Disruptive-Total subscale was the primary outcome) and Antisocial Behavior Scale; blinded clinicians rated change on the Clinical Global Impressions scale. Results: Compared with Basic treatment (PT + STIM [44.8 ± 14.6 mg/day] + placebo [1.88 mg/day ± 0.72]), Augmented treatment (PT + STIM [46.1 ± 16.8 mg/day] + risperidone [1.65 mg/day ± 0.75]) showed statistically significant improvement on the Nisonger Child Behavior Rating Form Disruptive-Total subscale (treatment-by-time interaction, p = .0016), the Nisonger Child Behavior Rating Form Social Competence subscale (p = .0049), and Antisocial Behavior Scale Reactive Aggression subscale (p = .01). Clinical Global Impressions scores were substantially improved for the 2 groups but did not discriminate between treatments (Clinical Global Impressions-Improvement score ≤2, 70% for Basic treatment versus 79% for Augmented treatment). Prolactin elevations and gastrointestinal upset occurred more with Augmented treatment; other adverse events differed modestly from Basic treatment; weight gain in the Augmented treatment group was minor. Conclusions: Risperidone provided moderate but variable improvement in aggressive and other seriously disruptive child behaviors when added to PT and optimized stimulant treatment. Clinical trial registration information-Treatment of Severe Childhood Aggression (The TOSCA Study), URL: http://clinicaltrials.gov, unique identifier: NCT00796302. (Copyright © 2014 American Academy of Child and Adolescent Psychiatry. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu